

Human Aggrecan (ADAMTS5-cleaved) Antibody

Monoclonal Mouse IgG_{2B} Clone # 726006

Catalog Number: MAB64891

DESCRIPTION		
Species Reactivity	Human	
Specificity	Detects human Aggrecan in direct ELISAs and Western blots. It specifically recognizes the C-terminal fragment of recombinant human Aggrecan released following cleavage by ADAMTS5.	
Source	Monoclonal Mouse IgG _{2B} Clone # 726006	
Purification	Protein A or G purified from hybridoma culture supernatant	
Immunogen	Aggrecan cleaved C-term aa 393-402 ARGSVILTVK Accession # P16112	
Formulation	Lyophilized from a 0.2 µm filtered solution in PBS with Trehalose. See Certificate of Analysis for details. *Small pack size (-SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.	

APPLICATIONS

Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.

	Recommended Concentration	Sample
Western Blot	2 μg/mL	See Below

DATA Western Blot rhAggrecan Detection of Human Aggrecan (ADAMTS5-cleaved) by Western Blot. Western blot shows recombinant human Aggrecan N-terminal and C-terminal fragments. PVDF membrane was probed with 2 µg/mL of Mouse Anti-Human Aggrecan Monoclonal Antibody (Catalog # MAB64891) followed by HRP-conjugated Anti-Mouse IgG Secondary Antibody (Catalog # HAF007). A specific band was detected for the Aggrecan C-terminal fragment at 117 approximately 55-60 kDa (as indicated). This experiment was conducted under reducing conditions and using Immunoblot Buffer 78 -Aggrecan 52 -37 -29 -

PREPARATION AND STORAGE

Reconstitution	Sterile PBS to a final concentration of 0.5 mg/mL.
Shipping	The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
	*Small pack size (-SP) is shipped with polar packs. Upon receipt, store it immediately at -20 to -70 °C

Stability & Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles.

- 12 months from date of receipt, -20 to -70 °C as supplied.
- 1 month, 2 to 8 °C under sterile conditions after reconstitution.
- 6 months, -20 to -70 °C under sterile conditions after reconstitution.

BACKGROUND

Aggrecan, also known as aggrecan 1, chondroitin sulfate proteoglycan, and large aggregating proteoglycan, is encoded by the AGC1 gene with gene aliases of SEDK; CSPGCP. As the key component of the cartilage extracellular matrix, aggrecan hydrates the collagen network and provides cartilage with its properties of compressibility and elasticity. Maintenance of aggrecan content is therefore critical to the function of the tissue and aggrecan degradation is an important factor in the erosion of articular cartilage in arthritic diseases (2). The deduced amino acid sequence of human aggrecan core protein consists of 2415 resides and predicts a signal peptide and domains of G1, IGD, G2, KS, CS-1, CS-2, and G3 (3). Two globular domains, G1 and G2, comprise the N-terminus of the proteoglycan and also contain link domains. The third globular domain, G3, corresponds to the C-terminus. The keratan sulfate (KS) and the chondroitin sulfate (CS) attachment domains are between G2 and G3. With KS and CS attached to the 250 kDa core protein, aggrecan monomers exist as a 1,000-2,000 kDa molecule. In addition, aggrecan monomers interact with hyaluronan through their G1 domain, resulting in larger aggregates containing 10-100 aggrecan monomers on a hyaluronan backbone (2).

Aggrecan can be cleaved by MMPs and ADAMTSs at the Asn360-Phe361 and Glu392-Ala393 bond in the IGD (residues are numbered based on Accession P16112), respectively (2). Inhibition of ADATMS4 and ADAMTS5 cleavage prevents aggrecan degradation in osteoarthritic cartilage, while mice with aggrecan resistant to MMP cleavage do not accumulate aggrean and develop normally (2, 4). Consisting of the G1, IGD and G2 domains, rhAggrecan can be used as a protein substrate for MMPs and ADAMTSs and in binding assays involving hyaluronan.

References:

- 1. Doege. K.J. et al. (1991) J. Biol. Chem. 266:894.
- 2. Malfait, A-M. et al. (2002) J. Biol. Chem. 277:22201.
- 3. Caterson, B. *et al.* (2000) Matrix Biol. **19**:333.
- 4. Little, C.B. et al. (2005) Mol. Cel. Biol. 25:3388.

Rev. 2/7/2018 Page 1 of 1

